- Home
- GIGM vs ZLAB Comparison
GIGM vs ZLAB Comparison
Compare GIGM & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIGM | ZLAB |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | Taiwan | China |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3M | 2.6B |
| IPO Year | 2002 | 2017 |
Fundamental Metrics
Financial Performance| Metric | GIGM | ZLAB |
|---|---|---|
| Price | $1.38 | $24.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $33.14 |
| AVG Volume (30 Days) | 3.3K | ★ 738.0K |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $460,156,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $26.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $1.11 | $15.96 |
| 52 Week High | $1.72 | $30.18 |
Technical Indicators
Market Signals| Indicator | GIGM | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 40.73 | 45.82 |
| Support Level | $1.32 | $24.24 |
| Resistance Level | $1.50 | $27.20 |
| Average True Range (ATR) | 0.08 | 0.95 |
| MACD | -0.00 | -0.18 |
| Stochastic Oscillator | 39.97 | 28.97 |
Price Performance
Historical ComparisonAbout GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. The only segment and principal business of the company is digital entertainment service business, that operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. The company operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown. The company generates majority revenue from Taiwan.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.